Synthetic biology specialist Synlogic will start phase 3 testing of a drug for rare metabolic disorder phenylketonuria (PKU) next year, after reporting solid proof-of-concept data.

Genzyme Corp. (Sanofi Genzyme) has disclosed sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, among others.

IN Jervis's introductory study, and in subsequent case reports of phenylketonuria (phenylpyruvic oligophrenia), a blonde hair colour and a fair skin have been noted in the large majority of the ...

PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

The 18-year-old's mom and sister work hard to give her the life she deserves as she battles a rare genetic condition ...

NEW YORK — MRC Holland said on Thursday that its blood-based assay for Temple, Kagami-Ogata, and Russell-Silver syndromes has received certification under Europe's In Vitro Diagnostic Regulation (IVDR ...

Under Emirates Health Services (EHS) theme "Future Health Now", EHS is participating in the 50th edition of Arab Health 2025, which kicks off tomorrow and runs until 30th January at the Dubai World ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...